The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Lori MufflyDuring the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Lori Muffly, Stanford University, Stanford, US. We asked, How should we treat a patient who has a molecular relapse after transplant?
How should we treat a patient who has a molecular relapse after transplant?
Muffly begins by defining what a molecular relapse is, and how it can be monitored and evaluated. She goes on to discuss therapy options for molecular relapse post allogeneic stem cell transplantation, such as tyrosine kinase inhibitors, CAR T-cells, and bispecific antibodies according to Philadelphia chromosome (Ph) status and ALL lineages. Finally, Muffly talks about a recent publication looking at outcomes of secondary transplants.
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?